Veeco Reports Fourth Quarter and Fiscal Year 2019 Financial Results
Fourth Quarter 2019 Highlights:Revenues of $113.2 million, compared with $99.0 million in the same period last yearGAAP net loss of […]
LPL Financial to Present at Credit Suisse’s 21st Annual Financial Services Forum
SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) — LPL Financial Holdings Inc. (NASDAQ: LPLA), parent company of leading retail investment […]
CarGurus Announces Fourth Quarter 2019 and Full-Year 2019 Results
Fourth Quarter Highlights:Total revenue of $158.2 million, an increase of 25% year-over-yearGAAP operating income of $13.6 million; non-GAAP operating income […]
Trupanion Reports Fourth Quarter and Full Year 2019 Results
SEATTLE, Feb. 13, 2020 (GLOBE NEWSWIRE) — Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, […]
Radius Health to Present at 9th Annual SVB Leerink Partners Global Healthcare Conference
WALTHAM, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) — Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & […]
Beyond Meat® to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
EL SEGUNDO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) — Beyond Meat, Inc. (NASDAQ: BYND), a leader in plant-based meat, announced […]
Chuy’s Holdings, Inc. to Announce Fourth Quarter 2019 Results on March 5, 2020
AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) — Chuy’s Holdings, Inc. (NASDAQ: CHUY) today announced that it will host a […]
Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million
LAKE FOREST, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) — Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced […]
Eton Pharmaceuticals to Present at the 9th Annual SVB Leerink Healthcare Conference
DEER PARK, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on […]
Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks
Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosaceaResults pave the way for […]
